Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Free Cash Flow (2024 - 2025)

Indivior Pharmaceuticals has reported Free Cash Flow over the past 2 years, most recently at -$245.0 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$245.0 million for Q4 2025, down 642.42% from a year ago — trailing twelve months through Dec 2025 was -$93.0 million (down 1428.57% YoY), and the annual figure for FY2025 was -$93.0 million, down 1428.57%.
  • Free Cash Flow for Q4 2025 was -$245.0 million at Indivior Pharmaceuticals, down from -$59.0 million in the prior quarter.
  • Over the last five years, Free Cash Flow for INDV hit a ceiling of $141.0 million in Q2 2025 and a floor of -$245.0 million in Q4 2025.